Skip to content


Rubraca (rucaparib) is a small molecule pharmaceutical. Rucaparib was first approved as Rubraca on 2016-12-19. It is used to treat ovarian neoplasms in the USA. It has been approved in Europe to treat ovarian neoplasms. The pharmaceutical is active against poly [ADP-ribose] polymerase 1. Rubraca's patents are valid until 2035-08-17 (FDA).
Trade Name Rubraca
Common Name Rucaparib
Indication ovarian neoplasms
Drug Class Poly-ADP-ribose polymerase inhibitors
Get full access now